RECURRENT PRIMARY PERITONEAL CARCINOMA
Clinical trials for RECURRENT PRIMARY PERITONEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY PERITONEAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY PERITONEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to outsmart recurrent ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding olaparib to selumetinib works better than selumetinib alone for women with recurrent or persistent ovarian or endometrial cancers that have a RAS pathway mutation. Selumetinib blocks enzymes that help cancer grow, while olaparib stops cance…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
Disease control Recruiting nowThis Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combinatio…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Ira Winer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail aims to boost immune attack on ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New vaccine combo shows promise in ovarian cancer fight
Disease control Recruiting nowThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRαDC) with an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells. The trial …
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy aims to control ovarian cancer and reduce painful fluid buildup
Disease control Recruiting nowThis study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup in the belly or chest. About 60 adul…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Supercharged immune cells take on tough ovarian cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with ovarian cancer that has returned or is resistant to standard platinum chemotherapy. The treatment uses a patient's own immune cells (T cells), which are trained in a lab to recognize and attack a protein called MUC1 fou…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental drug plus radiation shows promise for recurrent gynecologic cancers
Disease control Recruiting nowThis early-phase trial is testing the drug talazoparib together with radiation therapy in 24 women whose gynecologic cancer (ovarian, endometrial, cervical, or related cancers) has come back after previous treatment. Talazoparib blocks enzymes that cancer cells need to grow, and …
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cocktail of chemo, immunotherapy, and bladder drug takes on recurrent ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of two chemotherapy drugs (paclitaxel or nab-paclitaxel), an immunotherapy (pembrolizumab), and a bladder drug (mirabegron) can shrink tumors in people with ovarian cancer that has come back after initial treatment. About 20 adu…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New triple-drug attack shows promise for hard-to-treat ovarian cancer
Disease control Recruiting nowThis study tests a new combination of drugs for people whose ovarian cancer has returned after standard treatment. The drugs include a dual-target immunotherapy (QL1706), chemotherapy, and an oral anti-angiogenic agent (anlotinib). The goal is to see if this combo can shrink tumo…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New PET tracer could spot hidden cancers
Diagnosis Recruiting nowThis phase I trial is testing a new radioactive tracer called [18F]FTT, which is used with PET/CT scans to find tumor cells in people with solid tumors, including breast, ovarian, and other cancers. The study will enroll 300 participants and aims to see how well the tracer highli…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:07 UTC
-
Wearable tech aims to boost exercise and quality of life in cancer patients
Symptom relief Recruiting nowThis study tests whether a personalized physical activity program using a wearable device (like a Fitbit) can help people with ovarian or endometrial cancer exercise more and improve their quality of life. About 120 participants will either receive tailored activity goals and fee…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 04:00 UTC
-
Can we predict blood cancer in ovarian cancer survivors?
Knowledge-focused Recruiting nowThis study follows 2,000 people who have had ovarian or other solid cancers to learn why some later develop blood cancers like leukemia. Researchers will look at genetic changes in blood cells and treatment history to identify risk factors. No new treatments are being tested—the …
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC